Will the markov.bio AI copilot for drug discovery be influential in the R&D of a marketed drug? (Before 2030)

Prediction market on manifold. markov.bio is developping an "AI copilot for early-stage drug discovery." Will this product be credited for influential discoveries during early-stage developement of a drug that makes it to market? Makes it to market: approved for human use by the FDA or EMA. Credited: at least one press report, scientific publication, blog post, public statement from the drug manufacturer (not from markov.bio) that the product was influential during the developement of the drug. Testimony or interview of a member of the early stage developement team would also count if from a reliable outlet (enpts, C&EN,...). Influential: essential to a discovery, or accelerated a discovery significantly, or reduced costs significantly. Resolves No instantly if markov.bio folds or otherwise cease operation in the early stage drug discovery sector (so, exposure to founder's possible lack of buisness sense even if the science is fine). I reserved the right to resolves N/A on ambiguity after discussion in the comment (I foresee possible claims regarding ambiguity in the "influential" claim)

Liquidity: $170. Resolves: 1/1/2030.